DelveInsight’s Familial adenomatous polyposis Pipeline Insight, 2025” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Familial adenomatous polyposis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Familial Adenomatous Polyposis Pipeline? Click here to explore the therapies and trials making headlines @ Familial Adenomatous Polyposis Pipeline Outlook Report

Key Takeaways from the Familial Adenomatous Polyposis Pipeline Report

• On 02 September 2025, Parabilis Medicines Inc. announced a Phase 1/2 study to evaluate the safety, tolerability, PK, pharmacodynamics, and antitumor activity of FOG-001 as monotherapy and in combination with other anticancer agents in participants with advanced or metastatic solid tumors likely or known to have a Wnt pathway activating mutation (WPAM).
• DelveInsight’s Familial Adenomatous Polyposis Pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Familial Adenomatous Polyposis treatment.
• The leading Familial Adenomatous Polyposis Companies such as SLA Pharma, Recursion Pharmaceuticals, TherapyX, Eloxx Pharmaceuticals and others.
• Promising Familial Adenomatous Polyposis Therapies such as mFOLFOX-6, FOG-001, eRapa (encapsulated rapamycin), Eicosapentanoic Acid (EPA), Eflornithine, REC-4881, and others.

Want to know which companies are leading innovation in Familial Adenomatous Polyposis? Dive into the full pipeline insights @ Familial Adenomatous Polyposis Clinical Trials Assessment

The Familial Adenomatous Polyposis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Familial Adenomatous Polyposis Pipeline Report also highlights the unmet needs with respect to Familial Adenomatous Polyposis.

Familial Adenomatous Polyposis Overview

Familial adenomatous polyposis (FAP) is a hereditary disorder characterized by the development of numerous (sometimes hundreds or thousands) adenomatous polyps in the large intestine, typically beginning in the second decade of life. This condition is caused by a genetic mutation in the APC (adenomatous polyposis coli) tumor suppressor gene, which is inherited in an autosomal dominant pattern.

Familial Adenomatous Polyposis Emerging Drugs Profile

• ALFA: SLA Pharma

ALFA is a unique, novel oral formulation of highly purified eicosapentaenoic acid free fatty acid (EPA-FFA) in gastro-resistant capsules that is delivered to the gut at optimal pH allowing maximal absorption. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with Familial adenomatous polyposis.

• REC-4881: Recursion Pharmaceuticals

REC-4881 is an orally bioavailable, non-ATP-competitive allosteric small molecule inhibitor of MEK1 and MEK2 being developed to reduce polyp burden and progression to adenocarcinoma in people living with FAP. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Familial adenomatous polyposis.

If you’re tracking ongoing Familial Adenomatous Polyposis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Familial Adenomatous Polyposis Treatment Drugs

The Familial Adenomatous Polyposis Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Familial Adenomatous Polyposis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Familial Adenomatous Polyposis Treatment.
• Familial Adenomatous Polyposis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Familial Adenomatous Polyposis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Familial Adenomatous Polyposis market.

Familial Adenomatous Polyposis Companies

SLA Pharma, Recursion Pharmaceuticals, TherapyX, Eloxx Pharmaceuticals and others.

Familial adenomatous polyposis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Familial Adenomatous Polyposis Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

From emerging drug candidates to competitive intelligence, the Familial Adenomatous Polyposis Pipeline Report covers it all – check it out now @ Familial Adenomatous Polyposis Market Drivers and Barriers, and Future Perspectives

Scope of the Familial Adenomatous Polyposis Pipeline Report

• Coverage- Global
• Familial Adenomatous Polyposis Companies- SLA Pharma, Recursion Pharmaceuticals, TherapyX, Eloxx Pharmaceuticals and others.
• Familial Adenomatous Polyposis Therapies- mFOLFOX-6, FOG-001, eRapa (encapsulated rapamycin), Eicosapentanoic Acid (EPA), Eflornithine, REC-4881, and others.
• Familial Adenomatous Polyposis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Familial Adenomatous Polyposis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Genetic Disorders Research – discover what’s next for the Familial Adenomatous Polyposis treatment landscape in this detailed analysis @ Familial Adenomatous Polyposis Emerging Drugs and Major Players

Table of Content

1. Introduction
2. Executive Summary
3. Familial Adenomatous Polyposis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Familial Adenomatous Polyposis– DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Familial Adenomatous Polyposis Collaboration Deals
9. Late Stage Products (Phase III)
10. ALFA: SLA Pharma
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. REC-4881: Recursion Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Drug name: Company name
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. Drug name: Company name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Familial Adenomatous Polyposis Key Companies
23. Familial Adenomatous Polyposis Key Products
24. Familial Adenomatous Polyposis – Unmet Needs
25. Familial Adenomatous Polyposis – Market Drivers and Barriers
26. Familial Adenomatous Polyposis – Future Perspectives and Conclusion
27. Familial Adenomatous Polyposis Analyst Views
28. Familial Adenomatous Polyposis Key Companies
29. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/familial-adenomatous-polyposis-pipeline-insight